Foundation / Corporation
Alzheimer's Drug Discovery Foundation (ADDF)
11/09/18 5:00 PM EST Receipt
Grants to USA, Canada, and International nonprofits, universities, academic medical centers, and biotechnology companies for biomarkers research that will further the development of Alzheimer’s therapies. LOIs are due April 13. New applicants are advised to allow 1-2 business days for registration in the online application portal.
Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers that can (1) accurately diagnose these diseases, (2) properly stratify cohorts and enrich for patients with target pathology, (3) demonstrate target engagement for novel therapies, and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, many are expensive, invasive, or both, and have been concentrated on a small set of disease targets.
This Request for Proposals (RFP) seeks to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease and related dementias. This includes companion biomarkers for specific clinical-stage therapies and biomarkers with broader applicability across trials and therapeutic targets.
Neuroimaging: Positron emission tomography (PET) ligands for target engagement and pharmacodynamic measurements of novel and repurposed therapeutics, and novel magnetic resonance imaging (MRI) methods to measure structural, blood flow, and white matter changes in the brain
Cerebrospinal fluid (CSF) and blood-based biomarkers: Multiplex ELISA or mass spectrometry of specific target(s) or transcriptomics, proteomics, metabolomics, or lipidomics signatures
Functional activity measures: Electroencephalogram (EEG), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS)
Other novel approaches that are supported by compelling evidence
Biomarker targets: Current biomarker target areas of interest include, but are not limited to—
-Synaptic Integrity and/or Activity
-Vascular Injury & Blood-Brain Barrier Integrity
-Mitochondria & Metabolic function
-White Matter Changes
-The ADDF has limited interest in funding measures of cognition and function, as well as CSF assays of Aβ and tau levels.
Expectations: Priority is given to projects that—
-Validate biomarkers previously identified in samples from well-characterized human subjects
-Focus on biomarkers with a rational biological connection to the disease process and are supported by a reasonable body of preliminary data
-Use validated methods for quantifying and qualifying biomarkers. Developing novel technologies is a lower priority
The ADDF's mission is to accelerate discovery of a novel treatment for Alzheimer's disease and other related dementias. The ADDF seeks to fulfill its mission by providing funding for drug discovery and development projects. As a public charity, the ADDF’s funding must be used specifically for an approved scientific project that advances the ADDF's stated mission.
ADDF funding may be provided for approved personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials.
GrantWatch ID#: 181960
Average Award: $150,000 - $300,000 based on stage and scope of research.
The average duration is 1-2 years with potential for follow-on funding.
Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:
-Academic medical centers and universities or nonprofits
-Biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.
ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).
For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
It is highly recommended that you access the ADDF Funding Portal to begin the application process well in advance of any deadlines. Please note, new applicants should allow 1-2 business days for registration.
Letters of Intent and Full Proposals must be received by 5:00 PM EST on the deadline date.
-Letter of Intent: January 19, 2018
-Invited Full Proposal: February 9, 2018
-Letter of Intent: April 13, 2018
-Invited Full Proposal: May 11, 2018
-Letter of Intent: July 13, 2018
-Invited Full Proposal: August 10, 2018
-Letter of Intent: October 12, 2018
-Invited Full Proposal: November 9, 2018
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
For program-related inquiries, please contact:
Andrew Koemeter-Cox, PhD, Scientific Program Officer
For application submission inquiries, please contact:
Grants and Mission-Related Investments Team
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.